John Neoptolemos

John Neoptolemos led the ESPAC-1 trial establishing the survival benefit of chemotherapy versus chemoradiation in the adjuvant setting for resected pancreatic cancer, and subsequently led ESPAC-4 demonstrating superiority of gemcitabine plus capecitabine over gemcitabine alone. His ESPAC trials have fundamentally defined evidence-based adjuvant therapy for resected pancreatic cancer. He also led research on biomarker identification in pancreatic cancer surgical specimens to stratify outcomes. Neoptolemos has contributed extensively to European cooperative pancreatic cancer research and surgical oncology guidelines.